Trials / Completed
CompletedNCT00219102
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 336 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-09-22
- Last updated
- 2020-02-11
Locations
7 sites across 7 countries: United States, Belgium, Romania, Spain, Sweden, Switzerland, Ukraine
Source: ClinicalTrials.gov record NCT00219102. Inclusion in this directory is not an endorsement.